<DOC>
	<DOCNO>NCT00189657</DOCNO>
	<brief_summary>The main objective randomize trial compare 5FU/LV ( Mayo-Clinic regimen LV5FU2 ) LV5FU2 + irinotécan patient resect B2 C rectal cancer . Preoperative radiotherapy recommend mandatory . Main endpoint disease free survival . Secondary endpoint overall survival , time local recurrence , time distant metastasis , tolerance . A total 600 patient include trial .</brief_summary>
	<brief_title>5FU/VL Vs LV5FU2 + CPT11 Stage II-III Resected Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>rectal adenocarcinoma R0 surgery T3 , N0 , M0 T4 , N0 , M0 N1,2 , M0 chemotherapy start within 8 week surgery Age &gt; 18 Performance status ECOG &lt; 3 preoperative radiotherapy allow preoperative chemotherapy 5FU +/ LV allow Neutrophiles &gt; 1 500/mm3 ; Pl . &gt; 100 000/mm3 Transaminases &lt; 2 x UNL ; Alcalines Phosphatases &lt; 2 x UNL ; Bili &lt; 1.1 UNL creatininemia &lt; 120 µmol/l and/or clearance creatininemia &gt; 60 ml/mn Written inform consent inclusion postoperative radiotherapy Distant metastases Contraindication drug contain chemotherapy regimens Any serious active disease comorbid medical condition include digestive inflammatory disease Gilbert disease severe toxicity radiotherapy Pregnancy breast feed Absence contraception non menopausal woman Adult patient unable give inform consent intellectual impairment Concomitant participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>